Arena Pharmaceuticals (ARNA) 5.65 $ARNA
Arena starts PAH study ralinepag
Seeking Alpha - at Seeking Alpha - 13 mins ago
ARNA: 5.65 (+0.22)
Expect Arena's Belviq To Increase U.S. Market Share During 2015 Weight Loss Season
Clinically Sound Investor - at Seeking Alpha - 1 hr 49 mins ago
ARNA: 5.65 (+0.22)
A Deeper Look At Arena's Belviq Pricing
Spencer Osborne - at Seeking Alpha - 1 hr 51 mins ago
OREX: 5.75 (-0.03), ARNA: 5.65 (+0.22)
Most active Nasdaq-traded stocks
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
AGEN: 6.17 (+0.88), MU: 31.66 (-1.87), NPSP: 45.35 (+3.44), INTC: 36.60 (-0.16), ARNA: 5.65 (+0.22), AAPL: 109.25 (-2.76), SNDK: 83.57 (-13.47), CSCO: 28.05 (+0.26)
Orexigen's Contrave May Have Pricing Competition
Spencer Osborne - at Seeking Alpha - Mon Jan 12, 8:13AM CST
OREX: 5.75 (-0.03), VVUS: 3.30 (+0.09), ARNA: 5.65 (+0.22)
Arena Pharmaceuticals (ARNA) in Focus: Stock Falls 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 7:38AM CST
Arena Pharmaceuticals saw a big move last session, as the company’s shares fell by nearly 6% on the last trading day.
ARNA: 5.65 (+0.22)
Arena Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Ralinepag for Pulmonary Arterial Hypertension
PR Newswire - Mon Jan 12, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient dosing in a Phase 2 clinical trial of ralinepag, an oral, non-prostanoid prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH).
ARNA: 5.65 (+0.22)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), PFE: 32.77 (+0.12), INCY: 73.30 (+1.27), AMGN: 156.22 (+0.49), BMY: 62.18 (+1.86), ALKS: 68.61 (+3.47), CELG: 117.00 (+3.33), AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), JPM: 58.83 (-0.51), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), INFI: 15.15 (+0.38), ABBV: 65.76 (-0.02), CEMP: 26.62 (+0.84), SNY: 44.92 (+0.37), ARNA: 5.65 (+0.22), REGN: 413.33 (+2.29), NVS: 95.48 (-0.64)
Seeking Alpha's Biotech Weekly: Gilead Rises With Phenex, Bass's Patent Attack, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 09, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), ISIS: 73.34 (+1.08), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), INCY: 73.30 (+1.27), CVS: 97.20 (-0.72), AMGN: 156.22 (+0.49), ABBV: 65.76 (-0.02), ARNA: 5.65 (+0.22), NVS: 95.48 (-0.64)
Sales Of Arena's Belviq Close Out 2014 - What Will 2015 Bring?
Spencer Osborne - at Seeking Alpha - Fri Jan 09, 1:49PM CST
OREX: 5.75 (-0.03), ARNA: 5.65 (+0.22)
Arena Investors Should Watch New Pricing Of Belviq Closely
Spencer Osborne - at Seeking Alpha - Fri Jan 09, 11:20AM CST
OREX: 5.75 (-0.03), ARNA: 5.65 (+0.22)
Arena's APD334 Has Real Blockbuster Potential
Clinically Sound Investor - at Seeking Alpha - Fri Jan 09, 10:23AM CST
ARNA: 5.65 (+0.22)
Why VIVUS, Inc. Stock Descended 14% in December
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 8:03AM CST
What: Shares of VIVUS , a biopharmaceutical company focused on developing therapies to treat obesity and erectile dysfunction, tumbled 14% in December, based on data from S&P Capital IQ , after rival Orexigen Therapeutics received a...
OREX: 5.75 (-0.03), VVUS: 3.30 (+0.09), ARNA: 5.65 (+0.22)
Reveal Earnings Forecast for Arena Pharmaceuticals, Petrobras, Alibaba, Apple, Gilead Sciences, and Applied Materials
PR Newswire - Fri Jan 09, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Arena Pharmaceuticals (NASDAQ:ARNA), Petrobras (NYSE
BR), Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Gilead Sciences (NASDAQ:GILD), and Applied Materials (NASDAQ:AMAT).
PBR: 6.57 (-0.49), GILD: 101.21 (-1.00), AMAT: 23.66 (-0.58), AAPL: 109.25 (-2.76), ARNA: 5.65 (+0.22), BABA: 101.62 (-1.40)
Arena Pharmaceuticals Reports on Eisai's New Marketing Initiatives for BELVIQ® (lorcaserin HCl) CIV
PR Newswire - Fri Jan 09, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported on Eisai Inc.'s updated BELVIQ® marketing program with targeted new initiatives to address payers, patients and physicians.
ARNA: 5.65 (+0.22)
History Suggests MannKind Corporation's Afrezza Could Already Be Doomed
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 6:02AM CST
Source: MannKind. Last year was truly special for MannKind and its shareholders. For the first time since the company was founded in 1991 it received a drug approval from the Food and Drug Administration. Afrezza's mammoth opportunity The...
AZN: 70.79 (+1.35), VVUS: 3.30 (+0.09), SNY: 44.92 (+0.37), MNKD: 5.49 (-0.27), ARNA: 5.65 (+0.22)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 08, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OFED: 20.01 (+0.51), SIBC: 20.74 (+0.09), NBIX: 29.51 (+1.22), ANTH: 2.48 (-0.15), GALT: 3.65 (-0.11), BRID: 7.21 (-0.74), BIOD: 1.55 (-0.03), ARNA: 5.65 (+0.22)
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 08, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
LOXO: 11.35 (-0.45), ELOS: 10.92 (+0.05), AMBA: 61.90 (+0.07), RGEN: 25.30 (+1.06), ADXS: 12.09 (+0.79), NBIX: 29.51 (+1.22), PDFS: 16.94 (-0.56), HALO: 14.57 (+0.54), VLCCF: 5.08 (+0.49), PKT: 8.35 (-0.07), ARNA: 5.65 (+0.22)
Arena starts PAH study ralinepag
Seeking Alpha - at Seeking Alpha - 13 mins ago
ARNA: 5.65 (+0.22)
Expect Arena's Belviq To Increase U.S. Market Share During 2015 Weight Loss Season
Clinically Sound Investor - at Seeking Alpha - 1 hr 49 mins ago
ARNA: 5.65 (+0.22)
A Deeper Look At Arena's Belviq Pricing
Spencer Osborne - at Seeking Alpha - 1 hr 51 mins ago
OREX: 5.75 (-0.03), ARNA: 5.65 (+0.22)
Most active Nasdaq-traded stocks
AP - Mon Jan 12, 12:23PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
AGEN: 6.17 (+0.88), MU: 31.66 (-1.87), NPSP: 45.35 (+3.44), INTC: 36.60 (-0.16), ARNA: 5.65 (+0.22), AAPL: 109.25 (-2.76), SNDK: 83.57 (-13.47), CSCO: 28.05 (+0.26)
Orexigen's Contrave May Have Pricing Competition
Spencer Osborne - at Seeking Alpha - Mon Jan 12, 8:13AM CST
OREX: 5.75 (-0.03), VVUS: 3.30 (+0.09), ARNA: 5.65 (+0.22)
Arena Pharmaceuticals (ARNA) in Focus: Stock Falls 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 7:38AM CST
Arena Pharmaceuticals saw a big move last session, as the company’s shares fell by nearly 6% on the last trading day.
ARNA: 5.65 (+0.22)
Arena Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Ralinepag for Pulmonary Arterial Hypertension
PR Newswire - Mon Jan 12, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient dosing in a Phase 2 clinical trial of ralinepag, an oral, non-prostanoid prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH).
ARNA: 5.65 (+0.22)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), PFE: 32.77 (+0.12), INCY: 73.30 (+1.27), AMGN: 156.22 (+0.49), BMY: 62.18 (+1.86), ALKS: 68.61 (+3.47), CELG: 117.00 (+3.33), AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), JPM: 58.83 (-0.51), ISIS: 73.34 (+1.08), ALNY: 103.78 (+2.48), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), INFI: 15.15 (+0.38), ABBV: 65.76 (-0.02), CEMP: 26.62 (+0.84), SNY: 44.92 (+0.37), ARNA: 5.65 (+0.22), REGN: 413.33 (+2.29), NVS: 95.48 (-0.64)
Seeking Alpha's Biotech Weekly: Gilead Rises With Phenex, Bass's Patent Attack, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 09, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGEN: 6.17 (+0.88), JNJ: 104.58 (-0.36), NBIX: 29.51 (+1.22), ISIS: 73.34 (+1.08), KITE: 82.35 (+3.21), GILD: 101.21 (-1.00), INCY: 73.30 (+1.27), CVS: 97.20 (-0.72), AMGN: 156.22 (+0.49), ABBV: 65.76 (-0.02), ARNA: 5.65 (+0.22), NVS: 95.48 (-0.64)
Sales Of Arena's Belviq Close Out 2014 - What Will 2015 Bring?
Spencer Osborne - at Seeking Alpha - Fri Jan 09, 1:49PM CST
OREX: 5.75 (-0.03), ARNA: 5.65 (+0.22)
Arena Investors Should Watch New Pricing Of Belviq Closely
Spencer Osborne - at Seeking Alpha - Fri Jan 09, 11:20AM CST
OREX: 5.75 (-0.03), ARNA: 5.65 (+0.22)
Arena's APD334 Has Real Blockbuster Potential
Clinically Sound Investor - at Seeking Alpha - Fri Jan 09, 10:23AM CST
ARNA: 5.65 (+0.22)
Why VIVUS, Inc. Stock Descended 14% in December
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 8:03AM CST
What: Shares of VIVUS , a biopharmaceutical company focused on developing therapies to treat obesity and erectile dysfunction, tumbled 14% in December, based on data from S&P Capital IQ , after rival Orexigen Therapeutics received a...
OREX: 5.75 (-0.03), VVUS: 3.30 (+0.09), ARNA: 5.65 (+0.22)
Reveal Earnings Forecast for Arena Pharmaceuticals, Petrobras, Alibaba, Apple, Gilead Sciences, and Applied Materials
PR Newswire - Fri Jan 09, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Arena Pharmaceuticals (NASDAQ:ARNA), Petrobras (NYSE
BR), Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Gilead Sciences (NASDAQ:GILD), and Applied Materials (NASDAQ:AMAT). PBR: 6.57 (-0.49), GILD: 101.21 (-1.00), AMAT: 23.66 (-0.58), AAPL: 109.25 (-2.76), ARNA: 5.65 (+0.22), BABA: 101.62 (-1.40)
Arena Pharmaceuticals Reports on Eisai's New Marketing Initiatives for BELVIQ® (lorcaserin HCl) CIV
PR Newswire - Fri Jan 09, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported on Eisai Inc.'s updated BELVIQ® marketing program with targeted new initiatives to address payers, patients and physicians.
ARNA: 5.65 (+0.22)
History Suggests MannKind Corporation's Afrezza Could Already Be Doomed
Sean Williams, The Motley Fool - Motley Fool - Fri Jan 09, 6:02AM CST
Source: MannKind. Last year was truly special for MannKind and its shareholders. For the first time since the company was founded in 1991 it received a drug approval from the Food and Drug Administration. Afrezza's mammoth opportunity The...
AZN: 70.79 (+1.35), VVUS: 3.30 (+0.09), SNY: 44.92 (+0.37), MNKD: 5.49 (-0.27), ARNA: 5.65 (+0.22)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 08, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OFED: 20.01 (+0.51), SIBC: 20.74 (+0.09), NBIX: 29.51 (+1.22), ANTH: 2.48 (-0.15), GALT: 3.65 (-0.11), BRID: 7.21 (-0.74), BIOD: 1.55 (-0.03), ARNA: 5.65 (+0.22)
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 08, 5:10PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
LOXO: 11.35 (-0.45), ELOS: 10.92 (+0.05), AMBA: 61.90 (+0.07), RGEN: 25.30 (+1.06), ADXS: 12.09 (+0.79), NBIX: 29.51 (+1.22), PDFS: 16.94 (-0.56), HALO: 14.57 (+0.54), VLCCF: 5.08 (+0.49), PKT: 8.35 (-0.07), ARNA: 5.65 (+0.22)
